IL-12 immunoconjugate
US9580485B2 · kind B2 · utility
3Cited by
2References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 24, 2012 |
| Grant date | Feb 28, 2017 |
| Priority date | — |
| Expiry date | Mar 18, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Conjugate comprising interleukin-12 (IL-12) and a single chain targeting portion comprising two antigen binding sites. The targeting portion may comprise an antibody fragment such as a single chain diabody. The conjugate may be a single chain fusion protein. Use of single chain bivalent IL-12 immunocytokine for targeting the extra-cellular matrix (ECM) of tissues, particularly tumour neovasculature antigens, for example fibronectin. Use for treating cancer or pathological angiogenesis in a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.